G5-7

G5-7, an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr 1068 ) and STAT3 by binding to JAK2 . G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study In Vitro G5-7 (0-5 μM) inhibits EGFR tyrosine phosphorylation and downstream mTOR signaling and arrests the cell cycle at G2 phase. G5-7 does not directly inhibit EGFR activation. G5-7 (0-10 μM) comparably increases the abundance of markers (cleved-PARP and caspase 3) of apoptosis in parental LN229 cells and U87MG/EGFRvIII cells. G5-7 interacts with full-length JAK2. G5-7 significantly inhibits EGFR Tyr1068 phosphorylation but had no effect on EGFR Tyr1045 phosphorylation. G5-7 downregulates the downstream signaling of JAK by mTOR. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis. Cell Line: U87MG/PTEN cells. Concentration: 0-5 μM. Incubation Time: 6 hours. Result: Blocked EGFR phosphorylation and cell cycle at G2 phase to inhibit cell proliferation. In Vivo G5-7 (10 and 50 mg/kg, oral gavege) decreases VEGF secretion and exerts a potent antiangiogenic effect . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Cells (4 × 10 6 ) in 100 μl of serum-free DMEM were inoculated subcutaneously into 5- to 6-week-old female nude mice . Dosage: 10 and 50 mg/kg. Administration: Oral gavage. Result: Suppresses angiogenesis in tumors. Form:Solid IC50& Target:JAK2

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet